Progyny (Progyny) Interest Expense : $0 Mil (TTM As of Dec. 2023)

View and export this data going back to 2019. Start your Free Trial

What is Progyny Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Progyny's interest expense for the three months ended in Dec. 2023 was $ 0 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2023 was $0 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Progyny's Operating Income for the three months ended in Dec. 2023 was $ 14 Mil. Progyny's Interest Expense for the three months ended in Dec. 2023 was $ 0 Mil. GuruFocus does not calculate Progyny's interest coverage with the available data. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Progyny Interest Expense Historical Data

The historical data trend for Progyny's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Progyny Interest Expense Chart

Progyny Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

Get a 7-Day Free Trial

-0.06

Progyny Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Interest Expense	Get a 7-Day Free Trial															-	-	-	-	-

Progyny Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0 Mil.

Progyny (NAS:PGNY) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Progyny's Interest Expense for the three months ended in Dec. 2023 was $0 Mil. Its Operating Income for the three months ended in Dec. 2023 was $14 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Dec. 2023 was $17 Mil.

Progyny's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as

GuruFocus does not calculate Progyny's interest coverage with the available data.

The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Ben Graham prefers companies' interest coverage to be at least 5. Progyny Inc has enough cash to cover all of its debt. Its financial situation is stable.

Progyny (Progyny) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Progyny Inc (NAS:PGNY) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

1359 Broadway, New York, NY, USA, 10018

Website

https://www.progyny.com

Progyny Inc is a company engaged in specializing in fertility and family building benefits solutions. Its clients include employers across various industries. The fertility benefits solution consists of the treatment services (Smart Cycles), access to the Progyny network of high-quality fertility specialists that perform the Smart Cycle treatments and active management of the selective network of high-quality provider clinics.

Executives

David J Schlanger	director, officer: Executive Chairman	C/O PROGYNY, INC., 1359 BROADWAY, 2ND FLOOR, NEW YORK NY 10018
Michael E Sturmer	officer: President	48 LEDYARD RD, WEST HARTFORD CT 06117
Mark S. Livingston	officer: Chief Financial Officer	C/O PROGYNY, INC., 1359 BROADWAY, 2ND FL, NEW YORK NY 10018
Kevin K Gordon	director	155 S LIMERICK RD, LIMERICK PA 19468
Tpg Gp A, Llc	10 percent owner	301 COMMERCE STREET, SUITE 3300, FORT WORTH TX 76102
Peter Anevski	officer: Chief Executive Officer	C/O PROGYNY, INC., 1359 BROADWAY, 2ND FLOOR, NEW YORK NY 10018
Cheryl Scott	director	800 N. GLEBE ROAD, SUITE 500, ARLINGTON VA 22203
Norman Payson	director	800 N. GLEBE ROAD, SUITE 500, ARLINGTON VA 22203
Allison Swartz	officer: EVP, GC	C/O PROGYNY, INC., 1359 BROADWAY, NEW YORK NY 10018
Lloyd H Dean	director	185 BERRY STREET, SUITE 300, SAN FRANCISCO CA 94107
Monice Barbero	officer: EVP, GC and Secretary	C/O PROGYNY, INC., 1359 BROADWAY, NEW YORK NY 10018
Jon Winkelried	10 percent owner	C/O GOLDMAN, SACHS & CO., 85 BROAD STREET, NEW YORK NY 10004
Beth C Seidenberg	director
Jennifer Bealer	officer: EVP, General Counsel	C/O PROGYNY, INC., 245 5TH AVENUE, NEW YORK NY 10016
Malissia Clinton	director	333 THREE D SYSTEMS CIRCLE, ROCK HILL SC 29730